It wasn't all that long ago that GlaxoSmithKline was considering a spinoff for its HIV drugs division, ViiV Healthcare. Now, though, the company is hanging on tight to that business--and building it up, too.
Bristol-Myers Squibb is getting out of HIV R&D;, selling its pipeline to the GlaxoSmithKline-controlled ViiV Healthcare in a transaction worth as much as $3 billion.
Cost-effectiveness watchdogs in the U.K. dealt another couple of blows to pricey cancer drugs. The National Institute for Health and Care Excellence gave a final thumbs-down to Roche's breast cancer med Kadcyla, despite the drugmaker's discount offer.
The U.K. cost gatekeeper National Institute for Health and Care Excellence gave a one-two punch to Roche and Bristol-Myers Squibb's costly cancer drugs, rejecting Roche's breast cancer therapy Kadcyla and giving its thumbs-down to BMS' lung cancer med Opdivo.
A little more than two months after launching with a $55 million bankroll and a plan to develop next-gen cancer vaccines and immunotherapies, Third Rock startup Neon Therapeutics has allied with a leader in the checkpoint inhibitor space.
While pharma may not have the carbon footprint of energy or heavy manufacturing, it has other connections to environment and climate issues. The way climate change will affect public health, for instance, is a growing topic in global "green" pharma discussions, as is prescription drug pollution in the environment.
After winning FDA approval Monday, the latest multiple myeloma treatment--Empliciti, from Bristol-Myers Squibb and AbbVie--is about to hit the scene. And like its rivals in the field, it'll be pricey.
Partners Bristol-Myers Squibb and AbbVie picked up a speedy FDA approval for their cancer immunotherapy, preparing to launch a key cog in each company's oncology pipeline.
There's a reason immuno-oncology is among the hottest fields in biopharma today--and that's the $20 billion or so in 2022 sales that many analysts estimate. No wonder Bristol-Myers Squibb, Merck, AstraZeneca and Roche are speeding ahead with their research in the field, with Sanofi, Novartis and Pfizer racing to catch up.
Bristol-Myers Squibb has won yet another approval for its pioneering immuno-oncology drug Opdivo. The regulatory nod in advanced renal cell carcinoma, a form of kidney cancer, comes just one week after the FDA accepted the filing for priority review.